These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38721408)

  • 1. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Mustafayev K; Mallet V; Torres HA
    J Immunother Precis Oncol; 2024 May; 7(2):111-121. PubMed ID: 38721408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies.
    Mustafayev K; Torres H
    Clin Microbiol Infect; 2022 Oct; 28(10):1321-1327. PubMed ID: 35283317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.
    Shah NJ; Al-Shbool G; Blackburn M; Cook M; Belouali A; Liu SV; Madhavan S; He AR; Atkins MB; Gibney GT; Kim C
    J Immunother Cancer; 2019 Dec; 7(1):353. PubMed ID: 31847881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
    Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
    Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Xia Z; Zhang J; Chen W; Zhou H; Du D; Zhu K; Chen H; Meng J; Yang J
    Infect Dis Poverty; 2023 Sep; 12(1):87. PubMed ID: 37736699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review.
    Kuo L; Kuwelker S; Tsai E
    Ann Palliat Med; 2023 Nov; 12(6):1275-1294. PubMed ID: 37731304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.
    Zhao J; Zhang Y; Qin S; Zou B; Wang Y
    J Cancer; 2022; 13(14):3539-3553. PubMed ID: 36484006
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey.
    Tagliamento M; Remon J; Giaj Levra M; De Maria A; Bironzo P; Besse B; Novello S; Mezquita L
    JTO Clin Res Rep; 2023 Jan; 4(1):100446. PubMed ID: 36687558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.
    Yibirin M; Mustafayev K; Hosry J; Pundhir P; Klingen J; Yepez Guevara E; Granwehr BP; Kaseb A; Naing A; Patel S; Shah AY; Skoulidis F; Tawbi HA; Wang L; Miller E; Zhang HC; Zurita-Saavedra A; Torres HA
    Am J Gastroenterol; 2023 Sep; 118(9):1609-1617. PubMed ID: 37307533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation risk associated with immune checkpoint inhibitors in tumor treatment: a retrospective study.
    Yin Y; Liu BJ; Zhang YH; Qiu XY
    Jpn J Clin Oncol; 2024 Dec; 54(12):1288-1297. PubMed ID: 39180717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.
    Nakabori T; Abe Y; Higashi S; Hirao T; Kawamoto Y; Maeda S; Daiku K; Urabe M; Kai Y; Takada R; Yamai T; Ikezawa K; Uehara H; Ohkawa K
    JGH Open; 2022 May; 6(5):309-316. PubMed ID: 35601125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.
    Ding ZN; Meng GX; Xue JS; Yan LJ; Liu H; Yan YC; Chen ZQ; Hong JG; Wang DX; Dong ZR; Li T
    J Cancer Res Clin Oncol; 2023 May; 149(5):1993-2008. PubMed ID: 35767193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
    Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
    Pertejo-Fernandez A; Ricciuti B; Hammond SP; Marty FM; Recondo G; Rangachari D; Costa DB; Awad MM
    Lung Cancer; 2020 Jul; 145():181-185. PubMed ID: 32423643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
    Yoo S; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Yoo C; Ryoo BY; Choi J
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):898-907. PubMed ID: 34182151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
    Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
    Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?
    De Keukeleire SJ; Vermassen T; Nezhad ZM; Kerre T; Kruse V; Vlierberghe HV; Vermaelen K; Rottey S
    Immunotherapy; 2021 Apr; 13(5):409-418. PubMed ID: 33487052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
    Piaserico S; Messina F; Russo FP
    Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.